Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in ~30% of patients with breast cancer. However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR. We hypot...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Balko, Justin M, Cook, Rebecca S, Vaught, David B, Kuba, María G, Miller, Todd W, Bhola, Neil E, Sanders, Melinda E, Granja-Ingram, Nara M, Smith, J Joshua, Meszoely, Ingrid M, Salter, Janine, Dowsett, Mitch, Stemke-Hale, Katherine, González-Angulo, Ana M, Mills, Gordon B, Pinto, Joseph A, Gómez, Henry L, Arteaga, Carlos L
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3693569/
https://ncbi.nlm.nih.gov/pubmed/22683778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.2795
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak